The purpose of this Phase 2 study is to evaluate the efficacy and safety of an analgesic drug candidate, VVZ-149 Injections. The study is designed as randomized, double-blind, parallel, placebo-controlled study.
VVZ-149 is a dual antagonist of GlyT2 and 5HT2A. GlyT2 blockage increases inhibitory synaptic transmission by glycine in the spinal cord, resulting in a reduction of pain transmissions to the brain. 5HT2A blockage decreases descending serotonergic facilitatory modulation on pain transmission by the brain and reduces nociceptor activation in peripheral nerves, which are primary sources of pain in post-surgical pain. VVZ-149 has been shown to have comparable efficacy to morphine in well controlled (blind, complete randomization with a positive control) animal studies using rat models of post-operative pain and formalin-induced pain. The PK/PD study in animals indicates that therapeutic plasma concentration in human subjects will be 600-1,900 ng/ml. A clinical Phase 1 study performed in healthy subjects has shown no clinically significant adverse events up to a plasma concentration level of 3,261 ng/ml other than brief symptoms of mild nausea or dizziness, and mild somnolence when the plasma exposure level is more than 2,000 ng/ml.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
60
Experimental group will receive a loading dose of 1.8 mg/kg VVZ-149 intravenous infusion for 0.5 hour followed by a maintenance dose of 1.3 mg/kg/h VVZ-149 intravenous infusion for 7.5 hours.
Placebo group will receive the corresponding amount of placebo.
Massachusetts General Hospital
Boston, Massachusetts, United States
Brigham and Women's Hospital
Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Sum of Pain Intensity Difference over 8-hours post-dose (SPID8)
SPID8 using Numerical Pain Rating Scale (NRS, 0-10) measured up to 8 hours post-dose
Time frame: 8 hours post-dose
Difference of Opioid Consumption between Study Groups
Time frame: 0-2, 2-4, 4-6, 6-8, 8-12, 12-16, and 16-24 hours post-dose
Change of Pain Intensity (NRS)
Time frame: 9 and 24 hours post-dose
Change of Pain Relief (PR) assessed using a 6-point categorical scale
Time frame: 9 and 24 hours post-dose
Comparison of Global Measurement of Subject Satisfaction between Study Groups
Time frame: 8 and 24 hours post-dose
Change of Richmond Agitation-Sedation Scale
Time frame: 9 and 24 hours post-dose
Change of Incidence of Postoperative Nausea and Vomiting
Time frame: 8 and 24 hours post-dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.